What is the recommended treatment for COVID-19?

COVID-19 Treatment Recommendations

For outpatients with mild-to-moderate COVID-19 at high risk of progression, use nirmatrelvir/ritonavir as first-line therapy within 5 days of symptom onset; for hospitalized patients with severe disease requiring oxygen, use dexamethasone plus remdesivir, adding tocilizumab or baricitinib if inflammation persists despite corticosteroids. 1, 2, 3

Outpatient Treatment (Mild-to-Moderate Disease)

Risk Stratification First

High-risk patients include: age >60 years, immunocompromised status (including hematological malignancies, transplant recipients), unvaccinated individuals, and those with significant comorbidities 4, 1.

Antiviral Therapy (Within 5 Days of Symptom Onset)

First-line: Nirmatrelvir/Ritonavir (Paxlovid)

• Dosing: 300 mg/100 mg orally every 12 hours for 5 days 2, 3
• High certainty evidence for reducing hospitalizations in high and moderate-risk patients 2, 3
• Dose adjustment required if eGFR 30-59 mL/min: reduce to 150 mg/100 mg every 12 hours 2
• Critical caveat: Extensive drug-drug interactions through ritonavir—check Liverpool COVID-19 drug interaction tool before prescribing 2
• Contraindicated with severe hepatic or renal impairment 2

Second-line: Molnupiravir

• Use only when nirmatrelvir/ritonavir is contraindicated or unavailable 1, 3
• Advantage: no drug-drug interactions, can use in renal failure 1
• Important limitation: No longer recommended in EU due to concerns about immune escape variants in immunocompromised patients 1

For Immunocompromised Patients:

• Consider pre-exposure prophylaxis with long-acting monoclonal antibodies (sipavibart) if available 1
• May require combination or prolonged antiviral therapy (remdesivir + nirmatrelvir/ritonavir for 10+ days) for persistent viral replication, especially after B-cell depletion 1

What NOT to Use in Outpatients

• Do not use ivermectin 3
• Do not use corticosteroids in mild disease without hypoxia 4
• Do not use routine antibiotics without clinical justification 5

Hospitalized Patients (Moderate-to-Severe Disease)

Moderate Disease (Requiring Oxygen, SpO2 >90%)

Core Treatment:

1. Dexamethasone 6 mg daily (oral or IV) 4, 1
2. Remdesivir 200 mg IV day 1, then 100 mg daily for 5-10 days 4, 1

Add if seronegative and available:

• Convalescent plasma (within 72 hours of symptom onset) 4

If worsening despite dexamethasone with ongoing inflammation:

• Tocilizumab (anti-IL-6) OR
• Baricitinib (JAK inhibitor) OR
• Anakinra (anti-IL-1) 4, 1

Severe/Critical Disease (SpO2 <90%, ARDS, Mechanical Ventilation)

Core Treatment:

1. Dexamethasone (higher priority than antivirals) 4
2. Remdesivir 4, 1

Add second immunosuppressant for COVID-19-related inflammation:

• Tocilizumab or baricitinib (strongest evidence) 4, 1
• Vilobelimab if elevated suPAR with pneumonia 1

Anticoagulation in Hospitalized Patients

• All hospitalized patients: prophylactic-dose LMWH unless contraindicated 6
• ICU patients: continue prophylactic-dose LMWH 6
• Continue existing antiplatelet therapy for prior ACS or stroke 6

Special Populations

Hematological Malignancies/Transplant Recipients

• Higher mortality risk, particularly with AML, age >60, progressive disease 4
• Post-exposure prophylaxis with monoclonal antibodies if high-risk and unvaccinated 4
• May require combination antivirals for persistent infection 1
• Previous vaccination likely wiped out by transplant—revaccinate 6 months post-HSCT 4

Patients on Anticoagulation/Antiplatelet Therapy

• Continue existing DAPT for recent ACS with prophylactic anticoagulation 6
• Individualize decisions if on therapeutic anticoagulation plus DAPT (bleeding risk) 6
• New-onset atrial fibrillation: start therapeutic anticoagulation in hospitalized patients regardless of CHA2DS2-VASc score 6

Common Pitfalls to Avoid

1. Starting antivirals too late: Must initiate within 5 days of symptom onset for benefit 1, 2, 3
2. Missing drug interactions with nirmatrelvir/ritonavir: Always check interactions, particularly with immunosuppressants, anticoagulants, and cardiovascular medications 2
3. Using corticosteroids in mild outpatient disease: Dexamethasone should NOT be used without hypoxia 4
4. Prescribing antibiotics routinely: Only use with clinical justification (elevated WBC, CRP, PCT >0.5 ng/mL in critically ill patients) 5
5. Stopping existing antiplatelet/anticoagulation therapy: Generally continue unless significant bleeding risk 6

Treatment Algorithm Summary

Outpatient, high-risk, <5 days symptoms → Nirmatrelvir/ritonavir (check interactions) OR molnupiravir if contraindicated

Hospitalized, requiring oxygen → Dexamethasone + remdesivir + prophylactic LMWH

Hospitalized, worsening on steroids → Add tocilizumab or baricitinib

Critical/ICU → Dexamethasone + remdesivir + tocilizumab/baricitinib + prophylactic LMWH

Immunocompromised with persistent infection → Consider combination antivirals (remdesivir + nirmatrelvir/ritonavir)